Evofem Biosciences (EVFM)
(Delayed Data from OTC)
$0.01 USD
0.00 (-4.21%)
Updated Sep 13, 2024 03:38 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Evofem Biosciences, Inc. [EVFM]
Reports for Purchase
Showing records 1 - 20 ( 118 total )
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Phexxi Growth; Reverse Split Implemented; 2Q22 Financials; Raising PT to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Qualified Infectious Disease Product Status Awarded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Phexxi Preliminary Performance Packs Punch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Phexxi Market Access Expansion via Government Guidance; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Revenue Growth Anticipated; Operating Expense Control; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Top- and Bottom-Line Miss; Gross-to-Nets Challenges; Lowering PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Marketing Campaign Impact; Preferred Stock Offering; Reducing PT to $2.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Phexxi Awareness Building; Lowering PT to $4 Based on Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Phexxi Sales Slow Off the Blocks; 2020 Financial Results; Reducing PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Phexxi Marketing Campaign Accelerates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Phexxi Sales Trajectory Revamped; Modulating PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
EVO100 Pivotal Trial Initiated; Strategic Investment Secured; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Financial Results Reported; Phexxi Launch Perspectives; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Cash Replenished for Long Haul; Modulating PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Phexxi Wins FDA Approval; Spending to Rise Near-Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Financials; Phexxi Approval Decision Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Convertible Note Facility Established; Awaiting Phexxi Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Evofem Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
AMPOWER Data Sets Accepted by ACOG; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R